כל המחקרים
גיוסשלב 3התערבותי

A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

This study is testing a medication called Migalastat (a 20 mg capsule) for children aged 2 to 11 who have Fabry disease. Specifically, it's for those with a particular genetic change that Migalastat is known to help. We want to see how safe the medicine is, how the body uses it (pharmacokinetics), what effects it has (pharmacodynamics), and if it improves the health of children with Fabry disease. The study will last for about 12 months of treatment, with an option to continue afterwards. Children joining can't have been on other Fabry treatments recently or must have stopped them. This research hopes to find a safe and effective way to manage Fabry disease in a younger age group.

במבט חטוף

סטטוס
גיוס
שלב
שלב 3
נותן חסות
Amicus Therapeutics
יעד הרשמה
8
התחל
08 Jan 2026
השלמה משוערת
01 דצמבר 2028

על מה המחקר הזה?

Fabry disease is a rare genetic condition that can affect many parts of the body, including the kidneys, heart, and skin. It happens because the body can't make enough of a certain enzyme, which leads to a build-up of fats in cells. This can cause various health problems.

This study is looking at a medicine called Migalastat. It's designed for children aged 2 to under 12 years old who have Fabry disease, but only if they have a specific type of genetic change that Migalastat is known to work for. Think of it like a key fitting a specific lock. The main goal is to understand how safe the medicine is for these younger children, how their bodies process it, and if it helps to improve their Fabry disease symptoms over about a year.

By carefully studying Migalastat in this age group, researchers hope to gather important information that could potentially lead to it becoming a treatment option for more children with Fabry disease in the future. This is a common and important step in developing new medicines.

נקודות עיקריות

  • This study evaluates Migalastat for children (2-11 years) with Fabry disease.
  • It focuses on specific genetic types of Fabry disease that Migalastat can help.
  • The study assesses safety, how the body handles the medicine, and its effectiveness.
  • Treatment lasts about 12 months, with an option for longer-term follow-up.
  • Children currently on other Fabry treatments may need to pause them before joining.

מי עשוי להיות זכאי?

This study is for boys and girls with Fabry disease who are between 2 and 11 years old. A very important part of joining is that your child must have a specific type of genetic change (called an 'amenable GLA variant') that Migalastat is designed to work with. Your child should also have experienced at least one medical issue related to their Fabry disease.

Children can't join if they have severe kidney problems or are already on dialysis. Also, if your child has an allergy to Migalastat or similar medicines, or if they are currently taking other research medicines, they wouldn't be able to participate. If your child has had gene therapy, they also can't take part. Girls and boys who are able to have children must agree to use birth control during the study and for 30 days afterwards.

Additionally, if your child has recently received (within the last 14 days) or is currently receiving other specific Fabry disease treatments like enzyme replacement therapy (ERT), they would need to stop that treatment for the required time before joining.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. Is your child between 2 and 11 years old?
  2. Does your child have Fabry disease with a specific genetic change that Migalastat works for?
  3. Has your child had any health problems linked to Fabry disease?
  4. Does your child NOT have severe kidney problems or an allergy to Migalastat?
  5. Has your child NOT received gene therapy at any point?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If your child joins, they will take Migalastat as a capsule. The study involves two treatment periods totaling about 12 months, followed by an option to continue on the medicine in an extension phase. There will be no breaks in treatment between these active phases. If your child stops taking part at any time, they will have a safety check-up 30 days later.

Throughout the study, your child will have regular visits to the clinic for medical checks. This will include blood tests to measure the level of Migalastat in their body at certain times. These blood tests are done at specific points, including four samples over a 24-hour period within the first month, and then single samples at months 6 and 12. These tests help the doctors understand how the medicine is working and how safe it is. The total duration of active treatment for initial participation is about 12 months.

סיכונים ותועלות פוטנציאליים

Taking part in this study could offer some potential benefits, as your child would receive Migalastat, which may help manage their Fabry disease symptoms. However, as with any medicine, there are potential risks and side effects that will be explained to you in detail. These can range from mild to more serious, and the study team will monitor your child closely for any issues. It's important to remember that you are free to withdraw your child from the study at any time, for any reason, without it affecting their future medical care.

מיקומים (12)

  • Emory Genetics
    מיקוד מאומת
    אטלנטה, ארצות הברית· גיוס
  • University of Minnesota Masonic Children's Hospital
    מיקוד מאומת
    מיניאפוליס, ארצות הברית· גיוס
  • Atrium Health Levine Children's Hospital
    מיקוד מאומת
    שארלוט, ארצות הברית· גיוס
  • מרכז רפואי בית חולים לילדים סינסינטי
    מיקוד מאומת
    סינסינטי, ארצות הברית· גיוס
  • UPMC Children's Hospital of Pittsburgh
    מיקוד מאומת
    פיטסבורג, ארצות הברית· גיוס
  • Lysosomal and Rare Disorders Research and Treatment Center, Inc.
    מיקוד מאומת
    פיירפקס, ארצות הברית· גיוס
  • Universitair Ziekenhuis (UZ) Leuven
    מיקוד מאומת
    לוון, בלגיה· גיוס
  • Universitäetsklinikum Müenster (UKM) Klinik für Kinder- und Jugendmedizin - Allgemeine Paediatrie
    מיקוד מאומת
    Münster, Germany· גיוס
  • Kitasato University Hospital
    מיקוד מאומת
    Sagamihara, Japan· גיוס
  • Hospital Universitario de la Paz
    מיקוד מאומת
    מדריד, ספרד· גיוס
  • Great Ormond Street Hospital for Children NHS Foundation Trust
    מיקוד מאומת
    לונדון, הממלכה המאוחדת· עדיין לא מגייסים
  • קרן שירותי הבריאות הלאומית של אוניברסיטת מנצ'סטר
    מיקוד מאומת
    מנצ'סטר, הממלכה המאוחדת· גיוס

שאלות נפוצות

What is Fabry disease?

Fabry disease is a rare genetic condition where the body can't break down certain fatty substances, leading to their build-up in cells and causing health problems in various organs.

What is Migalastat?

Migalastat is a medication that helps the body's own faulty enzyme work better in some people with Fabry disease who have a specific genetic change.

How long will my child be in the study?

Your child will receive Migalastat treatment for about 12 months, with the possibility of continuing in an extension phase afterwards.

Will my child have to stop their current Fabry treatment?

If your child is on enzyme replacement therapy (ERT), they would need to stop it at least 14 days before starting this study.

Can my child choose to leave the study?

Yes, you can choose to withdraw your child from the study at any time without having to give a reason, and it won't affect their future medical care.

כיצד לגלות עוד

Amicus Therapeutics Patient Advocacy

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

מעוניינים להשתתף?

רשום את התעניינותך

שתף את הפרטים שלך וצוות המחקר עבור "A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) W…" ייצרו איתך קשר אם אתה עשוי להיות זכאי. תמיד התייעץ עם הרופא שלך לפני שאתה מסכים להשתתף.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.